Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - la fiebre hemorrágica, el Ébola - vacunas - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unión Europea - español - EMA (European Medicines Agency)

bavarian nordic a/s - vacuna modificada ankara - virus nórdico bávaro (mva-bn) - smallpox vaccine; monkeypox virus - otras vacunas virales, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 y 5. el uso de esta vacuna debe estar en conformidad con las recomendaciones oficiales.

Unión Europea - español - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vacunas - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Unión Europea - español - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - el dengue - vacunas - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Unión Europea - español - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infecciones por virus sincicial respiratorio - vacunas - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. ver secciones 4. 2 y 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. el uso de esta vacuna debe estar en conformidad con las recomendaciones oficiales.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - recombinante del virus de la estomatitis vesicular (cepa indiana) con una supresión de la glicoproteína de la envoltura, se sustituirá por el de zaire ébola (cepa de kikwit 1995) glicoproteína de superficie - la fiebre hemorrágica, el Ébola - vacunas - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. el uso de ervebo debe estar en conformidad con las recomendaciones oficiales.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

sanofi - aventis del peru s.a. - virus cyd del dengue, serotipo; virus cyd del dengue, serotipo; virus cyd del dengue, serotipo; virus cyd del dengue, serotipo; - polvo y disolvente para suspension inyectable - por pastilla; virus cyd del dengue, serotipo 1 4.500000 di; virus cyd del dengue, serotipo 3 4.500000 di; virus cyd del dengue, serotipo 2 4.500000 di; virus cyd del dengue, serotipo 4 4.500000 di; - otras vacunas virales

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

sanofi - aventis del peru s.a. - virus cyd del dengue, serotipo; virus cyd del dengue, serotipo; virus cyd del dengue, serotipo; virus cyd del dengue, serotipo; - polvo y disolvente para suspension inyectable - por ; virus cyd del dengue, serotipo 2 4.500000 di; virus cyd del dengue, serotipo 4 4.500000 di; virus cyd del dengue, serotipo 1 4.500000 di; virus cyd del dengue, serotipo 3 4.500000 di; - otras vacunas virales

Unión Europea - español - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - el dengue - vacunas - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 y 4. el uso de dengvaxia debe estar en conformidad con las recomendaciones oficiales.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

atlantic comerce trading sociedad anonima cerrada - tableta - por pastilla; isovaliaranato de cinc d4 30.000000 mg; strychnos ignatii d4 60.000000 mg; stepia officinalis d4 60.000000 mg; acido fosforico d4 60.000000 mg; bromato de potasio d4 30.000000 mg; - otras vacunas virales